Answer
Yes, in IKEMA, cardiac failure was reported in 7.3% of patients receiving isatuximab with carfilzomib and dexamethasone (4.0% Grade ≥3), with serious cardiac failure in 4.0% and fatal cardiac failure during treatment in 1.1%.
Sources for this answer
- SARCLISA 20mg/mL concentrate for solution for infusionSANOFI · emc · SmPC §4.8 Undesirable effects · Version 10Document updated
Sources checked